Targeting CDK9 with small molecule inhibitors represents a viable strategy for the treatment of several diseases, indicated especially by the deregulation of CDK9 activity in cancers, cardiac hypertrophy, HIV infections and pathological inflammation. This evidence concerns the gene CDK9 and HIV infectious disease.